Reliable biomarkers for clinical forms of multiple sclerosis: development of personalized strategies based on IFN type I immnue signature.
Year: 2013
Type: dissertation
Study design: Observational Study
Abstract: Multiple sclerosis (MS) is a highly heterogeneous disease and to date reliable plasma biomarkers that enable to distinguish among the different clinical forms of MS are lacking. The present work has identified blood biomarkers in 182 subjects (129 MS patients and 53 healthy controls) that were consecutively recruited as two independent cohorts. We found a significant lower expression of dipeptydil peptidase 4 (DPP4) and DPP activity in the plasma of MS patients with respect to healthy controls and DPP activity correlated inversely with clinical disability score in MS. Our results demonstrate that the divergent clinical and histology-based MS forms are associated with distinct profiles of circulating biomarkers, mostly chemokines and growth/angiogenic factors (HGF, Eotaxin/CCL11, MCP-1/CCL2, Rantes/CCL5, EGF, MIP-1β/CCL4, VEGF and FGFb); and with different gene expression levels in PBMCs of patients (CLU, IRF2 and LDLR). Responder patients to type I IFN displayed high levels of plasma IP10 and MCP-1, and a specific expression pattern of IFN stimulated genes.
Author: Marta Tejera Alhambra
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2949039012